scout

Podcasts

Recent Episodes

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care
Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care
Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.
ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia
Why Sexual and Gender Minority Care Is an Oncologic Imperative
Why Sexual and Gender Minority Care Is an Oncologic Imperative
Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.
How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025
Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.
Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center
Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology
Decision-Making Capacity: The Ethical Core of Patient-Centered Oncology
Michael Barish, PhD, discusses a novel cellular therapy for patients with glioblastoma that harnesses chlorotoxin, a peptide found in scorpion venom.
How Can Chlorotoxin-Directed CAR T-Cell Therapy Impact Glioblastoma Care?
Experts discussed supportive care and why it should be integrated into standard oncology care.
How Supportive Care Methods Can Improve Oncology Outcomes
Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.
What Were The Most Impactful GU Oncology Data From ESMO 2025?
Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

All series

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

Recent Episodes

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.

Oncology On the Go With ASTCT Talks

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

ONCOLOGY Decoded

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

FDA Approval Alert: The Need-to-Know

Oncology-on-the-Go with Daniel C. McFarland, DO

Oncology-on-the-Go with Daniel C. McFarland, DO